Melanoma Immunotherapy Study Launches
Evaxion Biotech announced the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, combined with checkpoint inhibitors in patients with advanced melanoma. The study is planned to occur at five clinical centers in Australia, targeting the recruitment of 46 patients. Early data readout from this Phase I/IIa is expected in H1 2021.
Lars Wegner, CEO of Evaxion Biotech, said in a press release issued on December 23, 2020, “We are very excited to start this Phase I/IIa study with EVX-02 further demonstrating the potential of Evaxion’s integrated PIONEER™ artificial intelligence platform to accelerate the discovery and development of a new generation of patient-specific cancer immunotherapies."
"We believe that the computational power behind the discovery of this compound shows that EVX-02 may have the potential to make a difference in malignant melanoma, which accounts for 1% of skin tumors and causes of 60% mortality due to skin cancers.”